Hegel, Adorno and the origins of immanent criticism

‘Immanent criticism' has been discussed by philosophers of quite different persuasions, working in separate areas and in different traditions of philosophy. Almost all of them agree on roughly the same story about its origins: It is that Hegel invented immanent criticism, that Marx later developed it, and that the various members of the Frankfurt School, particularly Adorno, refined it in various ways, and that they are all paradigmatic practitioners of immanent criticism. I call this the Continuity Thesis. There are four different claims that interest me. (i) Hegel is the originator of immanent criticism. (ii) Hegel's dialectical method is that of immanent criticism. (iii) Adorno practises immanent criticism and endorses the term as a description of his practice. (iv) Adorno's dialectical method is fundamentally Hegelian. In this article, I offer an account of immanent criticism, on the basis of which, I evaluate these four claims and argue that the Continuity Thesis should be rejected

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

Livelihood trade-offs in the commercialisation of multiple-use NTFP: lessons from marula (Sclerocarya birrea subsp. caffra) in southern Africa

Commercialisation of non-timber forest products (NTFP), apart from the multitude of benefits, is often associated with trade-offs in terms of traditional and cultural livelihoods. This paper presents a holistic assessment of livelihood trade-offs involved in commercialisation of marula (Sclerocarya birrea subsp. caffra), a multiple-use NTFP species in southern Africa. The study was conducted\ud at two sites in South Africa (Bushbuckridge district and Ubombo district) and one in Namibia (former Ovamboland). Some of the key features of the study include the household use and trade in marula products, the biological aspects of the marula resources, marketing and trade of the species and policies associated with its utilisation. The paper also highlights the important and diverse role that marula\ud has in local livelihoods and in contributing to the forms of livelihood capital like human, social, financial, natural and physical capital. Likely trade-offs in terms of\ud livelihoods with increasing commercialisation of marula are discussed, along with potential threats and opportunities from commercialisation